Nabihah Tayob

Harvard University — United States

Medicine · Health Sciences

34h-index5.2kcitations447works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(93), HER2/EGFR in Cancer Research(81), Cancer Immunotherapy and Biomarkers(70), Monoclonal and Polyclonal Antibodies Research(67), Cancer Treatment and Pharmacology(59)

Publications447 total

Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution
Breast Cancer Research and Treatment·2026
A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer
Clinical Cancer Research·2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
Nature Communications·2025· 1 citedOpen Access
Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 2 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 6 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 1 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 4 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
page 1 of 23Next →

Frequent Co-authors

Sara M. Tolaney(19), Eric P. Winer(16), Elizabeth A. Mittendorf(12), Tianyu Li(10), Ian E. Krop(10), Susan Murray(8), Harold J. Burstein(8), Fernando J. Martínez(7), Amit G. Singal(7), Ann H. Partridge(6), Nadine Tung(6), Kevin R. Flaherty(5), Qingchun Jin(5), Nancy U. Lin(5), Fasiha Kanwal(5), Hashem B. El‐Serag(5), Ursula A. Matulonis(5), Panagiotis A. Konstantinopoulos(5), Jorge A. Marrero(5), Neehar D. Parikh(5)